Clinical Trials
3 trialsNCT03905148 2026-01-07
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
BeOne Medicines
Phase 1 Completed
NCT02022982 2024-03-19
PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02510001 2021-07-13
MErCuRIC1
University of Oxford
Phase 1 Completed